Through innovation and cutting-edge research we have developed and established therapies, making them better and safer with the added protection of patent protection. Our mission is to create products that deliver on significant unmet medical needs. Our primary focus is on established therapies were we apply innovative technology to deliver improved patient outcomes.
Solvotrin’s R&D focus is on four therapeutic areas:
Aspirin is one of the most prescribed drugs in the world and is used to prevent clotting, heart attacks, stroke and death in patients with cardiovascular disease. With 75% of patient having detectable levels of gastric bleeding there is a significant opportunity to improve this established therapy. With the goal of protecting the stomach and intestine lining. We have discovered a way to achieve this through the deactivation of active Aspirin which can later be reactivated naturally by enzymes naturally present in the blood. With our patented technology we have found a way to liberate active aspirin only when it is in the bloodstream. Thus the drug maintains its therapeutic qualities, without the damaging gastrointestinal side effects.
Iron deficiency anaemia is caused by a lack of iron and is the most common vitamin and mineral deficiency in the UK. According to the World Health Organization (WHO), iron deficiency is the top nutritional disorder in the world. With our patented iron formulation we used microencapsulation to produce a product which results in significantly less iron-related oxidative stress and damage to the gut cells than standard ferrous sulfate. In addition, our targeted release is clinically proven to deliver twice the absorption of standard ferrous sulfate. We continue to innovate on our current iron product (Active Iron) recognizing the challenge with the absorption of multiple vitamins and minerals we have created a range of combination products with a targeted release mechanism to ensure optimum absorption of all vitamins and minerals. We are developing bespoke solutions for Pregnancy and Children for launch in 2019.
The final two therapies in early stage development are dermatology where we are currently looking at the role of pro drugs in anti-inflammatory conditions such as Psoriasis. We are also assessing the role of pro drugs in a number of oncology treatments.